IH IHI iShares US Medical Devices ETF Loading... : Bullish and Bearish Analyst Opinions

Bearish view on IHI as medtech companies face margin compression from rising semiconductor component costs (PCBs, analog) that cannot be passed through, with 2021/22 pricing cycle as benchmark for P&L impacts.

Author says he added med-tech, calling it “over punished for no reason.” Med-tech (e.g., surgical robots, implants) often trades at depressed multiples during interest-rate fears; author sees a fundamental disconnect. He is betting on mean-reversion as earnings remain stable. Regulatory headwinds, slower hospital spending, or a broader market sell-off.

Bearish view on medtech stocks/ETF as the speaker expects further multiples compression tomorrow, driven by a directional bearish view on the sector's valuation.

European defense stocks have structural growth.

RBC is "overweight" the Healthcare sector. Calvasina notes that during oil crises, "both the pharma group and the health care equipment and services group tend to outperform." When geopolitical risk rises, capital rotates out of high-beta tech and into defensive sectors with stable earnings. Healthcare offers a dual benefit: it acts as a safe haven (defensive) and currently possesses "good valuation appeal" relative to the broader index. LONG Healthcare (XLV) and specifically Pharmaceuticals (XPH) and Medical Devices (IHI) as a hedge against geopolitical volatility. A rapid de-escalation in the Middle East could trigger a "risk-on" rotation back into Tech, causing defensive sectors to lag.

Oz praises FDA Commissioner Marty Makary for making "difficult and brave decisions" to "get devices approved more rapidly." A regulatory environment focused on speed and reducing red tape lowers the cost of bringing new medical devices to market and accelerates revenue generation for device makers. LONG. Faster approvals equal faster cash flow. Potential safety recalls if approvals are too rushed (referenced as "controversy" in the transcript).